Biotechnology company Circio Holding ASA (OSE:CRNA) on Thursday reported new in vivo data showing that its AAV-circVec 4.0 platform achieved up to 50-fold higher gene expression in the eye versus conventional mRNA-based AAV following local delivery, establishing ophthalmology as a new development focus.
The data also showed a 10-fold expression advantage at a 90% lower dose, supporting the platform's potential to increase potency, reduce toxicity, and lower costs for gene therapies targeting genetic and degenerative eye diseases.
In cardiac applications, previously reported 40-fold expression gains were reproduced, with ex vivo analyses showing circVec expression in 80% of heart cells after low-dose systemic AAV delivery, validating the durability advantage of circular RNA over mRNA.
Separately, Circio raised NOK68.6m (approximately USD7m) in a 50% oversubscribed rights issue and private placements in Q1 2026 to accelerate circVec R&D, with attached warrants exercisable in June 2026 potentially extending funding into the second half of 2027.
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
Oracle partners AstraZeneca for AI-enabled healthcare innovation
Medtronic confirms separation of MiniMed
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
US FDA grants orphan drug designation for Lundbeck's asedebart
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Lilly to acquire Merida Biosciences in USD2.875bn deal
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations